We are building health confidence through our work at the intersection of science and technology in the spaces of MedTech AI, dermatology, gastroenterology, and
Thank you to everyone we met at the #Jefferies Global #HealthcareConference.
It was a pleasure to present #Cosmo and to speak with members of the investment community.
For anything we didn’t get to cover, our IR team is always glad to talk: https://t.co/Ox8uBUFa3H
Today is #WorldScienceDayforPeaceandDevelopment
Our R&D and #TranslationalScience team share a great drive to further science through curiosity and knowledge. We are proud to contribute to the wider scientific community through this most recent publication.
One week ago, Cosmo announced positive topline Phase 2 results for rifamycin 1% topically acting gel in distal #UlcerativeColitis and #UlcerativeProctitis.
Read more https://t.co/NiLqak8vKg
Investigational – not approved for use
What an inspiring few days at #FallClinical 2026! We are so honored to have been part of such an incredible event. Thank you to everyone who stopped by to connect with our team. We're looking forward to continuing the conversation! #FallClinical#FC26
We are pleased to share Phase 2 results from our study of rifamycin 1% topically acting gel in distal ulcerative colitis and ulcerative proctitis. Investor call today at 4:00 pm CEST.Full announcement & call details: https://t.co/NiLqak7XUI
Investigational – not approved for use.
Cosmo is excited to join the dermatology community at the 26th Annual Fall Clinical Dermatology Conference, Oct. 8-11. We look forward to connecting, exchanging perspectives and engaging in conversations shaping dermatologic care.
#FallClinical#FC26
That’s a wrap on #EADVCongress 2026 in Vienna!
From connecting with colleagues to sharing scientific research exploring androgen receptor antagonism in male pattern hairloss, it was a great few days of scientific exchange and collaboration.
#Cosmo#Innovation
We will participate at H.C. Wainwright Biotech on Tap 2026 Conference
If you are attending and would like to connect, please reach out to our Investor Relations team to arrange a meeting: https://t.co/Ox8uBUFHTf
We look forward to engaging with the investment community.
Our #CFO, Svetlana Sigalova will hold one-to-one meetings with institutional investors during the #conference.
Please, reach out to our Investor Relations team to arrange a meeting: https://t.co/Ox8uBUFa3H
We look forward to engaging with the investment community.
#Cosmo
CEO interview | Schweizer Aktien
In a recent interview with https://t.co/qg08p1Lvzt, #CEO@giovannidinapol discusses @CosmoConfidence 's business model, financial discipline, R&D activities and the company’s evolution as a broader healthcare business
https://t.co/wYqqWgayOK
The 3rd Barcelona Hair Meeting brought experts together to advance the latest science and innovation in #HairLoss. Cosmo was proud to contribute to the dialogue on male pattern hair loss and connect with leaders shaping the future of #AndrogeneticAlopecia.
#BCNHair2026
334,000+ colonoscopies. Real-world evidence at scale.
Results from the CADeNCE study, showed improved adenoma detection associated with access to the #GIGenius system across endoscopists of all experience levels.
https://t.co/GDYZz3kOs2
#Cosmo@MedtronicGI
Advancing the science of #hairloss at #BCNHair2026. Join the Cosmo team in Barcelona for a luncheon on male pattern #hairloss, several engaging discussions and presentations & two posters on investigational AGA research. Connect with our team on-site to learn more!
We will participate at the HC Wainwright Global Investment Conference.
Our CEO, @giovannidinapol will present how #Cosmo continues to deliver sustainable long-term #growth through disciplined execution, a differentiated business model and a focused, innovative #pipeline
𝗔𝘁 𝗖𝗼𝘀𝗺𝗼, 𝘄𝗲 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗲 𝘄𝗶𝘁𝗵 𝗽𝘂𝗿𝗽𝗼𝘀𝗲 - to improve lives, advance care, and develop solutions where they’re needed most.
By combining a deep understanding of science and technology, we are advancing research and therapeutic innovation.
𝗛𝗲𝗮𝗱𝗶𝗻𝗴 𝘁𝗼 #ESDR2026 𝗶𝗻 𝗛𝗲𝗶𝗱𝗲𝗹𝗯𝗲𝗿𝗴?
Don’t miss Qima CSO Dr. Edelkamp’s poster on new research exploring androgen receptor antagonism in male pattern hair loss.
Poster: #515
#Cosmo#Pharma#Innovation#Healthcare